Mindstate Design Labs

We're making every therapeutically valuable emotion available on demand in pharmaceutical form.

Our Osmanthus platform is an ensemble of AI models that synthesize the world’s largest datasets of psychoactive pharmacology and phenomenology, quantitatively pinpointing the combination of neurotransmitter receptor activity that underlies various emotional as well as cognitive and perceptual states.

Our lead program MSD-001 is designed to be rapid-acting and produce heightened emotional and cognitive flexibility without hallucinations. MSD-001 is currently in human trials, and will be the base ingredient for multiple drug combination "emotions in a bottle" such as empathy, awe, clarity, or beauty.

High-Level Overview

Mindstate Design Labs is a clinical-stage AI neuroengineering company focused on developing next-generation psychedelic therapeutics to address the mental health crisis. Their AI-powered platform, Osmanthus, synthesizes extensive datasets of psychoactive drug effects and biochemical data to map how specific neurotransmitter receptor combinations produce distinct emotional and cognitive states. Their lead product, MSD-001, is designed to deliver rapid-acting, therapeutically valuable emotional and cognitive flexibility without hallucinations, currently undergoing human trials. This innovation aims to make a wider range of emotional states accessible on demand in pharmaceutical form, serving patients with mental health disorders and advancing psychotropic therapy[1][2][3][5].

Origin Story

Founded in 2021 by Dillan DiNardo, a former biotech venture capitalist, Mindstate Design Labs emerged from the idea of using AI to decode and design precise psychedelic experiences. DiNardo and his team leveraged large-scale natural language processing and machine learning to analyze over 70,000 trip reports and biochemical data, a novel approach in psychedelic drug development. Early traction included backing from Y Combinator and prominent tech investors, and the submission of an IND to the FDA for clinical trials of MSD-001, marking a pivotal moment in translating AI insights into clinical-stage therapeutics[2][3][4].

Core Differentiators

• AI-Driven Drug Discovery: Osmanthus platform uses multi-agent large language models, Bayesian neural networks, and custom embeddings to integrate phenomenological and pharmacological data, enabling precise targeting of neurotransmitter receptors.
• Novel Therapeutic Approach: MSD-001 is a “psychedelic tofu” base molecule (5-MeO-MiPT) that can be combined with other drugs to create specific altered states of consciousness with minimized side effects like hallucinations.
• Clinical Validation: Successfully completed Phase I trials demonstrating psychoactive benefits without hallucinations, confirmed by brain imaging data.
• Unique Dataset Utilization: First to systematically mine and quantify psychedelic trip reports from diverse sources including Reddit, drug forums, and clinical datasets for drug design.
• Customization and Safety: Ability to design “emotions in a bottle” such as empathy, awe, or clarity, with improved safety and accessibility compared to traditional psychedelics[1][3][4][5].

Role in the Broader Tech Landscape

Mindstate Design Labs rides the convergence of AI, neuropharmacology, and mental health innovation, addressing a critical need for safer, more effective psychiatric treatments. The timing is crucial as mental health disorders rise globally and psychedelic therapies gain regulatory acceptance. Their platform leverages advances in AI to overcome traditional drug discovery bottlenecks by mechanistically linking drug chemistry to subjective experience, a major challenge in neuroscience. By enabling precise modulation of brain states, Mindstate could expand the therapeutic scope of psychedelics beyond current indications, influencing both biotech and AI-driven drug development ecosystems[1][4].

Quick Take & Future Outlook

Looking ahead, Mindstate Design Labs is poised to expand its pipeline of AI-designed psychotropic therapies, potentially transforming mental health treatment paradigms with customizable, trip-free psychedelic medicines. Trends shaping their journey include growing acceptance of psychedelic medicine, advances in AI for drug discovery, and increasing demand for personalized mental health solutions. Their influence may evolve from a niche psychedelic innovator to a broader neuroengineering platform driving new classes of emotional and cognitive therapeutics, democratizing access to mental health care with precision and safety[5]. This aligns with their mission to unlock safe, reliable access to a wider range of emotional and cognitive states, marking a new frontier in AI-enabled neuropharmacology.